INCB123667 is named as a drug or biological intervention in 4 clinical trials in our USA, UK and Ireland trial registers, 4 of which are recruiting. The lead sponsor is Incyte Corporation. Registered phases: Phase 1, Phase 3 and Phase 2. Conditions studied include Ovarian Cancer; Renal Impairment; Hepatic Insufficiency.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07214779 | Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression Ovarian Cancer |
Phase 3 | Recruiting |
| NCT07023627 | A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (ClinicalTrials.gov ↗) Ovarian Cancer |
Phase 2 | Recruiting |
| NCT07559396 | A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease (ClinicalTrials.gov ↗) Renal Impairment |
Phase 1 | Recruiting |
| NCT07559474 | A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment (ClinicalTrials.gov ↗) Hepatic Insufficiency, Liver Diseases |
Phase 1 | Recruiting |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Ovarian Cancer | 2 |
| Renal Impairment | 1 |
| Hepatic Insufficiency | 1 |
| Liver Diseases | 1 |
| Lead sponsor | Trials |
|---|---|
| Incyte Corporation | 4 |
| Register | INCB123667 trials |
|---|---|
| Clinical trials in USA | 4 |
| Clinical trials in UK | 2 |
| Clinical trials in Ireland | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how INCB123667 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists INCB123667 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.